Published through 2026-11-02 17:05 UTC · Automated cloud publishing.
Bausch + Lomb Q3 Contact Lens Sales Rise; New Dry Eye Survey Released
Understand the event
Bausch + Lomb reported third-quarter 2026 contact lens revenues of $286 million, representing a 5 percent increase compared to the same period in the prior year. This financial performance aligns with earlier estimates and confirms continued positive momentum in the vision care segment, even when adjusted for constant currency rates. No conflicting reports have emerged regarding these specific revenue figures or growth percentages. In addition to the financial results, the company released multinational research on October 30, 2026, highlighting a significant gap between self-reported dry eye symptoms and formal diagnoses. The NESTS survey indicated that up to 39 percent of respondents across five countries reported experiencing dry eye symptoms, yet many lacked a corresponding clinical diagnosis. This new study underscores potential challenges in patient identification and treatment within the broader eye care market, complementing the company's strong quarterly sales data. The combination of robust contact lens revenue growth and insights into diagnostic disparities marks a notable development in Bausch + Lomb’s recent reporting cycle.
AI-generated from reporting · updated 4 days ago
Developments
- 10-30 04:00 · 1 reportsBausch + Lomb releases dry eye diagnosis gap researchEyeSmart:Bausch + Lomb Reports Q3 Growth and Highlights Dry Eye Diagnosis Gap
- 10-29 23:37 · 1 reportsBausch + Lomb contact lens sales rise 5% in Q3Eyewear Intelligence:Bausch + Lomb reports 5% rise in Q3 contact lens revenue
Reporting timeline
Follow the reporting for different perspectives.
- EyeSmartBausch + Lomb Reports Q3 Growth and Highlights Dry Eye Diagnosis Gap
Bausch + Lomb released multinational research on October 30, 2026, revealing a gap between self-reported dry eye symptoms and formal diagnoses. The NESTS survey found up to 39% of respondents in five countries reported regular symptoms, compared to a maximum of 25% with healthcare professional diagnoses. Over 80% modified behavior due to symptoms, while up to one-quarter of those consulting professionals felt guidance was inadequate. This announcement coincides with strong third-quarter 2026 financial results reported on October 28, showing total revenue growth of 7% to US$1.375 billion. Pharmaceuticals grew 11%, driven by a 42% surge in MIEBO® revenue; Vision Care rose 5%; and Surgical increased 9%. Chairman Thomas J. Appio noted consistent delivery against commitments.
- Eyewear IntelligenceBausch + Lomb reports 5% rise in Q3 contact lens revenue
Bausch + Lomb reported third-quarter 2026 contact lens revenues of $286 million. This figure represents a 5 percent increase compared to the same period in the prior year. When adjusted for constant currency rates, the growth was 6 percent. The data reflects company-reported financial results for the specific quarter ending in late 2026.
Event coverage trend
Current coverage 3·Comparable peak 19(10-30 04:00)·Comparable change over 24 hours –
Trends compare continuously observed participants only; coverage may be narrower than the current total. Point, click or use arrow keys to inspect hourly values.